drugset / Trial / NCT07150975
Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight Subjects
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is a multicenter, randomized, open-label, parallel-group phase III clinical trial comparing the efficacy and safety of GZR18 Injection and semaglutide (Wegovy®) in adult obese or overweight subjects, aiming to evaluate the efficacy and safety of GZR18 Injection in this population.
Timeline
- Start
- 2025-09-23
- Primary completion
- 2027-06-30
- Completion
- 2027-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bofanglutide | Protein / enzyme biologic | — | Subcutaneous |
| Comparator | Semaglutide | Peptide | 2.4 mg | Subcutaneous |
Indications
No indication recorded.